Academic Journal of Medicine & Health Sciences, 2023, 4(4); doi: 10.25236/AJMHS.2023.040405.
Liangwu Chen1, Weimin Zhu2
1Department of Infectious Disease, The Frist Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, 400016, China
2Department of Infectious Disease, The Frist Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, 400016, China
Acute-on-chronic liver failure (ACLF) is a syndrome that can lead to severe dysfunction and decompensation of liver synthesis, metabolism, detoxification, and biotransformation. ACLF with bacterial infections can lead to making the disease worse and increasing short-term mortality. However, the clinical manifestations of patients are not typical and the waiting time for bacterial culture is long. Finding reliable early diagnostic indicators, starting effective treatment, and giving timely preventive measures can reduce the mortality of patients and improve the clinical prognosis. This article describes the mechanism of acute-on-chronic liver failure with bacterial infections, summarizes its early diagnostic indicators, and reviews the treatment and prevention methods.
acute-on-chronic liver failure, bacterial infections, diagnosis, therapy, prevention
Liangwu Chen, Weimin Zhu. Diagnosis, Treatment, and Prevention of Acute-on-Chronic Liver Failure with Bacterial Infections. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 4: 26-32. https://doi.org/10.25236/AJMHS.2023.040405.
[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018). Chinese Journal of Clinical Infectious Diseases. 2019, 37(1):1-9.
[2] FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018; 67(10):1870-1880.
[3] LIU XQ, ZHANG XY, YING Y, et al. The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study. Infect Dis Poverty. 2021;10(1):44.
[4] WANG L, FOUTS DE, STARKEL P, et al. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016; 19(2):227-239.
[5] JALAN R, FERNÁNDEZ J, WIEST R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310-1324.
[6] LANGE CM, MOREAU R. Immunodysfunction in Acute-on-Chronic Liver Failure. Visc Med. 2018; 34(4): 276-282.
[7] EKPANYAPONG S, REDDY KR. Infections in Cirrhosis. Curr Treat Options Gastroenterol. 2019; 17(2): 254-270.
[8] ALBILLOS A, LARIO M, ÁLVAREZ-MON M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014; 61(6):1385-1396.
[9] BEENSMEIER C, TRIANTAFYLLOU E, BRENIG R, et al. CD14+ CD15- HLA-DR- myeloid- derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut. 2018; 67(6):1155-1167.
[10] CAI J, ZHANG M, HAN T, JIANG HQ,et al. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017; 96(37): e8057.
[11] ZHANG Z, MA K, YANG Z, et al. Development and Validation of a Clinical Predictive Model for Bacterial Infection in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Infect Dis Ther. 2021; 10(3):1347-1361.
[12] ZHANG X, CHEN P, GAO H, et al. Bacterial Infection and Predictors of Mortality in Patients with Autoimmune Liver Disease-Associated Acute-On-Chronic Liver Failure. Can J Gastroenterol Hepatol. 2018; 2018:5108781.
[13] HE X, CHEN L, CHEN H, et al. Diagnostic Accuracy of Procalcitonin for Bacterial Infection in Liver Failure: A Meta-Analysis. Bioinorg Chem Appl. 2021;2021:5801139. Published 2021 Jul 5, 80-88.
[14] LIU W, PU Y, ZHU C, et al. Establishment of a scoring model for early diagnosis of infection associated with liver failure. Ann Hepatol. 2022; 27(4):100713.
[15] DONG R, WAN B, LIN S, et al. Procalcitonin and Liver Disease: A Literature Review. J Clin Transl Hepatol. 2019; 7(1):51-55.
[16] LIN S, YAN Y, WU Y, et al. Procalcitonin as a biomarker for diagnose of bacterial infection in patients with acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol. 2020;44(2):e32-e34.
[17] JIANG ML, XU F, HU JL, et al. Clinical value of IL-6,CRP,PCT and endotoxin in predicting the risk of liver failure with bacterial infection [J]. Chinese Journal of Nosocomiology, 2020, 30(20): 3062- 3065.
[18] LIN S, HUANG Z, WANG M, et al. Interleukin-6 as an early diagnostic marker for bacterial sepsis in patients with liver cirrhosis. J Crit Care. 2015;30(4):732-738.
[19] CONG S, MA T, DI X, et al. Diagnostic value of neutrophil CD64, procalcitonin, and interleukin-6 in sepsis: a meta-analysis. BMC Infect Dis. 2021;21(1):384.
[20] ZOU H, YE ZL, LIU SX, et al. The value of neutrophil CD64 index in the diagnosis of patients with sepsis in intensive care unit [J]. Chinese Critical Care Medicine, 2021, 33(6):676-679.
[21] XIONG KG, KE KY, KONG JF, et al. Clinical application value of nCD64 combined with PCT in patients complicated with acute-on-chronic liver failure and bacterial infection [J]. The Journal of Practical Medicine, 2019, 35(18):2914-2917.
[22] ZACCHERINI G, WEISS E, MORESA R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep. 2020; 3(1):100176.
[23] YANG L, WU T, LI J, et al. Bacterial Infections in Acute-on-Chronic Liver Failure. Semin Liver Dis. 2018; 38(2):121-133.
[24] TAN LM, MENG YM, LONG TT, et al. Clinical significance of PCT,DD,and CRP levels in patients with infection in acute-on-chronic liver failure [J]. The Journal of Practical Medicine, 2018, 34(3): 410-415.
[25] LIN S, YAN YY, WU YL, et al. Development of a novel score for the diagnosis of bacterial infection in patients with acute-on-chronic liver failure. World J Gastroenterol. 2020; 26(32): 4857-4865.
[26] JUNG SH, HAHN YK, OH S, et al. Advection Flows-Enhanced Magnetic Separation for High-Throughput Bacteria Separation from Undiluted Whole Blood. Small. 2018; 14(34):e1801731.
[27] TJANDRA KC, RAM-MOHAN N, ABE R, et al. Diagnosis of Bloodstream Infections: An Evolution of Technologies towards Accurate and Rapid Identification and Antibiotic Susceptibility Testing. Antibiotics (Basel). 2022;11(4):511.
[28] WOUTERS Y, DALLOTAUX D, CHRISTENHUSZ A, et al. Droplet digital polymerase chain reaction for rapid broad-spectrum detection of bloodstream infections. Microb Biotechnol. 2020; 13(3): 657-668.
[29] ABRAM TJ, CHERUKURY H, OU CY, et al. Rapid bacterial detection and antibiotic susceptibility testing in whole blood using one-step, high throughput blood digital PCR. Lab Chip. 2020; 20(3):477-489.
[30] MONTGOMERY JL, ASNFORD LN, WITTWER CT. High-resolution DNA melting analysis in clinical research and diagnostics. Expert Rev Mol Diagn. 2010; 10(2):219-240.
[31] HOJ TR, MCNEELY B, WEBBER K, et al. A pentaplex real-time PCR assay for rapid identification of major beta-lactamase genes KPC, NDM, CTX, CMY, and OXA-48 directly from bacteria in blood. J Med Microbiol. 2021; 70(12):001465.
[32] LU AQ, YANG KL, GUAN YJ, et al. Research advances in the diagnosis and treatment of acute-on-chronic liver failure with infection [J]. Journal of Clinical Hepatology, 2019, 35(11): 2596-2599.
[33] CHEUNG A, TANNA S, ISON MG. Infectious Complications in Critically Ill Liver Failure Patients. Semin Respir Crit Care Med. 2018; 39(5):578-587.
[34] FERNÁNDEZ J, PRADO V, TREBICKA J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019; 70(3):398-411.
[35] PIANO S, TONON M, ANGELI P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol. 2021; 27(3):437-445.
[36] WIESER A, LI H, ZHANG J, et al. Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis. Dig Liver Dis. 2019; 51(9): 1300-1307.
[37] Chinese Society of Infectious Diseases, Chinese Medical Association. Expert consensus on diagnosis and treatment of end-stage liver disease complicated with infections [J]. Journal of Clinical Hepatology, 2018,34(9):1862-1872.
[38] ENGELMANN C, BERG T. Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure. Visc Med. 2018; 34(4):261-268.
[39] DONG Y, SUN D, WANG Y, et al. Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. BMC Infect Dis. 2022;22(1):23.
[40] CARACENI P, VARGAS V, SOLÁ E, et al. The Use of Rifaximin in Patients With Cirrhosis. Hepatology. 2021; 74(3):1660-1673.
[41] KANG SH, LEE YB, LEE JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther. 2017; 46(9):845-855.
[42] BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017; 66(6):1727-1738.
[43] FERNÁNDEZ J, TANDON P, MENSA J, et al. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology. 2016;63(6):2019-2031.
[44] KUMAR M, KAINTH S, CHOUDHURY A, et al. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. 2019; 13(6): 800-813.
[45] FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2020; 18(4):963-973.